IgA Nephropathy: Galactose-Deficient IgA1 and the Mesangial Trap

What IgA Nephropathy Is and Why It Matters

IgA nephropathy, first described by Jean Berger and Nicole Hinglais in 1968, is the most common primary glomerulonephritis worldwide. Its prevalence varies strikingly by geography — highest in East Asia (where it accounts for 40–50% of primary glomerular disease biopsies) and Europe, and notably rare in individuals of African ancestry.

It matters because it is a leading cause of kidney failure in young adults. Once dismissed as benign 'Berger's disease', longitudinal data show that 30–40% of patients reach end-stage kidney disease (ESKD) over 20–30 years, and the average patient loses kidney function for decades of life expectancy.

• Peak age: second and third decades of life; male predominance in Western cohorts.
• Primary vs secondary: primary IgAN is idiopathic; secondary forms occur with cirrhosis, celiac disease, and HIV.
• Systemic cousin: IgA vasculitis (Henoch–Schönlein purpura) shares the same Gd-IgA1 immunopathology but adds palpable purpura, arthralgias, and abdominal pain — the two are considered a disease spectrum.

The Mechanism: The Four-Hit Hypothesis

IgAN follows a well-defined four-hit pathogenic cascade, all centered on a defectively glycosylated antibody.

• Hit 1 — Aberrant IgA1: Mucosal plasma cells overproduce galactose-deficient IgA1 (Gd-IgA1). The hinge region of IgA1 normally carries O-linked sugars capped with galactose; in IgAN, reduced activity of the glycosyltransferase C1GALT1 and its chaperone Cosmc (C1GALT1C1) leaves the hinge missing galactose, exposing bare N-acetylgalactosamine (GalNAc) residues.
• Hit 2 — Autoantibodies: The exposed GalNAc epitopes are recognized as neo-antigens. The immune system generates anti-glycan IgG (and IgA) autoantibodies against them.
• Hit 3 — Immune complexes: Autoantibodies bind Gd-IgA1, forming large circulating Gd-IgA1–IgG immune complexes too big to clear normally.
• Hit 4 — Mesangial trap: Complexes lodge in the glomerular mesangium, activate mesangial cells and the alternative and lectin complement pathways, and drive cytokine release, proliferation, and matrix expansion — with sclerosis and proteinuria following.

The cytokines APRIL and BAFF drive Gd-IgA1–producing B cells, which is why they are now prime drug targets.

Clinical Presentation and Classic Signs

IgAN wears two very different clinical masks, split largely by age.

• Synpharyngitic gross hematuria: the classic presentation in children and young adults. Visible (macroscopic) hematuria appears within 1–3 days of a mucosal infection — usually pharyngitis, sometimes gastroenteritis. This tight timing distinguishes it from post-streptococcal GN, where hematuria lags the infection by 1–3 weeks. Episodes recur and resolve spontaneously.
• Asymptomatic microscopic hematuria + proteinuria: the more common presentation in adults, often found incidentally on routine urinalysis. Dysmorphic red cells and red-cell casts indicate a glomerular source.

Less commonly, patients present with nephrotic-range proteinuria, a rapidly progressive glomerulonephritis (RPGN) picture from crescentic disease, acute kidney injury (often from gross-hematuria-associated tubular red-cell injury/ATN), hypertension, or already-established chronic kidney disease. Truly asymptomatic microscopic hematuria alone still warrants surveillance, as proteinuria and hypertension are the strongest drivers of progression.

Diagnosis: Biopsy, Immunofluorescence, and the Oxford MEST-C Score

There is no serologic test that establishes IgAN — diagnosis requires a kidney biopsy. Serum Gd-IgA1 levels are elevated in most patients and are a promising biomarker, but are not yet a stand-alone diagnostic.

• Immunofluorescence (the defining finding): dominant or codominant granular mesangial IgA deposits, typically with C3 and lambda light chains.
• Light microscopy: mesangial hypercellularity and matrix expansion; crescents in aggressive disease.
• Electron microscopy: electron-dense deposits in the mesangium (and paramesangium).

Biopsies are graded by the Oxford (MEST-C) classification, which independently predicts prognosis:

• M — Mesangial hypercellularity (M0/M1)
• E — Endocapillary hypercellularity (E0/E1)
• S — Segmental glomerulosclerosis (S0/S1)
• T — Tubular atrophy/interstitial fibrosis (T0 <25%, T1 26–50%, T2 >50%) — the strongest predictor of progression
• C — Crescents (C0/C1/C2)

Risk is refined with the International IgAN Prediction Tool, which combines eGFR, blood pressure, proteinuria, and MEST scores.

Management: Mechanism-Based and Rapidly Evolving

Under the 2025 KDIGO guideline, therapy is escalated to a proteinuria target of <0.5 g/day (ideally <0.3 g/day), because residual proteinuria drives progression.

• Foundational (supportive) care: maximally tolerated ACE inhibitor or ARB (RAAS blockade lowers intraglomerular pressure and proteinuria), plus an SGLT2 inhibitor (e.g., dapagliflozin/empagliflozin) for nephroprotection, with blood-pressure and sodium control.
• Endothelin/RAAS dual blockade: sparsentan, a dual endothelin-A/angiotensin-II receptor antagonist, replaces (not adds to) the ARB; carries a hepatotoxicity/teratogenicity REMS.
• Gut-targeted immunomodulation: targeted-release budesonide (Nefecon/Tarpeyo), a 9-month course delivered to the ileal Peyer's-patch mucosa where Gd-IgA1 B cells originate.
• Complement inhibition: iptacopan, an oral factor-B inhibitor of the alternative pathway.
• B-cell cytokine blockade: APRIL inhibitor sibeprenlimab and dual BAFF/APRIL inhibitor atacicept target the source of pathogenic IgA1.

Systemic glucocorticoids are used cautiously in high-risk disease given infection risk; crescentic/RPGN forms may need immunosuppression.

Mimics, Pitfalls, and Do-Not-Miss Points

Because IgAN is common and its labs are nonspecific, several traps recur.

• Don't confuse it with post-streptococcal GN. The timing is the tell: IgAN hematuria is synpharyngitic (0–3 days), PSGN is post-infectious (1–3 weeks), and PSGN shows low serum C3 — C3 is normal in IgAN.
• Don't overlook IgA vasculitis (HSP). The same immunopathology with purpura, arthritis, and GI bleeding is the systemic form — examine the skin and joints.
• Isolated microscopic hematuria still needs follow-up. Progression is driven by proteinuria and hypertension, which can develop years after a benign-seeming presentation.
• Secondary IgAN mimics primary. Cirrhosis, celiac disease, and HIV cause secondary mesangial IgA deposition — screen when the picture fits.
• Rapid GFR decline = look for crescents. A crescentic (RPGN) transformation is a do-not-miss emergency requiring urgent biopsy and immunosuppression.
• Gross-hematuria AKI is usually red-cell-cast tubular injury and often reversible — don't reflexively attribute it to progressive scarring.

IgA nephropathy versus its common glomerular mimics

Feature	IgA nephropathy	Post-streptococcal GN	Alport syndrome	Thin basement membrane
Hematuria timing vs infection	Concurrent (synpharyngitic, 0–3 days)	Delayed (1–3 weeks post-strep)	Persistent microscopic ± episodic gross	Persistent microscopic
Immunofluorescence	Dominant mesangial IgA (+ C3)	Granular IgG/C3 'starry sky', humps	No immune deposits	No immune deposits
Complement (C3)	Normal	Low C3 (transient)	Normal	Normal
Key extra-renal clue	Often none; overlaps IgA vasculitis	Recent GAS pharyngitis/impetigo	Sensorineural deafness, lenticonus	Benign family history of hematuria
Prognosis	30–40% ESKD over decades	Usually self-limited in children	Progressive ESKD (COL4 mutation)	Benign, non-progressive